• Je něco špatně v tomto záznamu ?

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

R. Kapoor, PR. Ho, N. Campbell, I. Chang, A. Deykin, F. Forrestal, N. Lucas, B. Yu, DL. Arnold, MS. Freedman, MD. Goldman, HP. Hartung, EK. Havrdová, D. Jeffery, A. Miller, F. Sellebjerg, D. Cadavid, D. Mikol, D. Steiner, . ,

. 2018 ; 17 (5) : 405-415. [pub] 20180312

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012775
E-zdroje Online Plný text

NLK ProQuest Central od 2002-05-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-05-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-05-01 do Před 2 měsíci
Psychology Database (ProQuest) od 2002-05-01 do Před 2 měsíci

Odkazy

PubMed 29545067
DOI 10.1016/s1474-4422(18)30069-3
Knihovny.cz E-zdroje

BACKGROUND: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. METHODS: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18-58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0-6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0-5·5 vs 6·0-6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. FINDINGS: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66-1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74-1·53; nominal p=0·753) or the T25FW (0·98, 0·74-1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40-0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108-221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. INTERPRETATION: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. FUNDING: Biogen.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012775
003      
CZ-PrNML
005      
20190415142202.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1474-4422(18)30069-3 $2 doi
035    __
$a (PubMed)29545067
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kapoor, Raju $u National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: r.kapoor@nhs.net.
245    10
$a Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension / $c R. Kapoor, PR. Ho, N. Campbell, I. Chang, A. Deykin, F. Forrestal, N. Lucas, B. Yu, DL. Arnold, MS. Freedman, MD. Goldman, HP. Hartung, EK. Havrdová, D. Jeffery, A. Miller, F. Sellebjerg, D. Cadavid, D. Mikol, D. Steiner, . ,
520    9_
$a BACKGROUND: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. METHODS: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18-58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0-6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0-5·5 vs 6·0-6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. FINDINGS: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66-1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74-1·53; nominal p=0·753) or the T25FW (0·98, 0·74-1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40-0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108-221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. INTERPRETATION: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. FUNDING: Biogen.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    12
$a progrese nemoci $7 D018450
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a ruka $x patofyziologie $7 D006225
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x aplikace a dávkování $x škodlivé účinky $x farmakologie $7 D007155
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chronicko-progresivní roztroušená skleróza $x farmakoterapie $x patofyziologie $7 D020528
650    _2
$a natalizumab $x aplikace a dávkování $x škodlivé účinky $x farmakologie $7 D000069442
650    12
$a hodnocení výsledků zdravotní péče $7 D017063
650    _2
$a výzkumný projekt $7 D012107
650    12
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ho, Pei-Ran $u Biogen, Cambridge, MA, USA.
700    1_
$a Campbell, Nolan $u Biogen, Cambridge, MA, USA.
700    1_
$a Chang, Ih $u Biogen, Cambridge, MA, USA.
700    1_
$a Deykin, Aaron $u Biogen, Cambridge, MA, USA.
700    1_
$a Forrestal, Fiona $u Biogen, Cambridge, MA, USA.
700    1_
$a Lucas, Nisha $u Biogen, Cambridge, MA, USA.
700    1_
$a Yu, Bei $u Biogen, Cambridge, MA, USA.
700    1_
$a Arnold, Douglas L $u Montreal Neurological Institute, Montreal, QC, Canada; NeuroRx Research, Montreal, QC, Canada.
700    1_
$a Freedman, Mark S $u University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
700    1_
$a Goldman, Myla D $u University of Virginia, Charlottesville, VA, USA.
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
700    1_
$a Havrdová, Eva Kubala $u First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Jeffery, Douglas $u Piedmont HealthCare, Mooresville, NC, USA.
700    1_
$a Miller, Aaron $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Sellebjerg, Finn $u Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Cadavid, Diego $u Biogen, Cambridge, MA, USA.
700    1_
$a Mikol, Dan $u Biogen, Cambridge, MA, USA.
700    1_
$a Steiner, Deborah $u Biogen, Cambridge, MA, USA.
700    1_
$a ,
773    0_
$w MED00006921 $t The Lancet. Neurology $x 1474-4465 $g Roč. 17, č. 5 (2018), s. 405-415
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29545067 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190415142225 $b ABA008
999    __
$a ok $b bmc $g 1392085 $s 1051080
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 17 $c 5 $d 405-415 $e 20180312 $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace